Pfizer Inc. (PFE) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: Setup is modestly constructive — consensus is a manageable bar and the non-COVID business has clear momentum, but the stock has underperformed XLV by ~15 points since Q1 earnings, suggesting the market is pricing in execution risk rather than a beat; the single biggest swing factor is whether Vyndaqel/Vyndamax net pricing holds in the face of intensifying AMVUTTRA competition.

Heading into Q2 2026, the consensus bar for PFE looks achievable: Street is modeling $14.38B in revenue (down ~1.5% YoY) and $0.68 adjusted EPS, both of which sit below the Q1 2026 actuals of $14.45B and $0.75, respectively, reflecting the expected COVID back-half weighting and a tougher Vyndaqel net-price comparison. Management's posture has been notably confident since Q1 — CFO Denton explicitly signaled the company "probably would have raised guidance" absent COVID seasonality, and CEO Bourla reiterated at Goldman Sachs (June 8) that the non-COVID business has "significant upside" to 2026 guidance, with launched and acquired products growing 22% operationally in Q1. Estimate revisions have been modestly negative since Q1 (2Q26 EPS consensus drifted from $0.680 to $0.678), suggesting the Street has not yet fully credited management's bullish tone — a gap that represents potential cushion if Padcev (+39% in Q1), Nurtec (+41%), and Eliquis continue to outperform. The stock has significantly underperformed XLV since Q1 earnings (PFE -5.4% vs. XLV +11.7% indexed), trading at just 8.6x NTM P/E — a discount that reflects LOE skepticism rather than near-term earnings risk. The key wildcard is the Alnylam AMVUTTRA second-line demand normalization disclosed July 30: pent-up demand from stabilizer patients has cleared, which could reduce the near-term competitive headwind on Vyndaqel, but Alnylam's accelerating first-line share gains remain a structural pressure on Pfizer's largest in-line product.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a low-to-moderate bar — revenue and EPS estimates sit below Q1 actuals, reflecting COVID seasonality headwinds. Vyndaqel trajectory is the bigger swing factor; Padcev's continued 30%+ growth is the upside lever.

Table 1 — Current Quarter Snapshot (Q2 2026)

Sources: Visible Alpha Consensus and Actuals Data; Pfizer Q1 2026 Earnings Release (May 5, 2026); Pfizer 8-K (June 18, 2026). Consensus estimates as of August 4, 2026.

Table 2 — Beat/Miss History (Last 8 Quarters)

Total Revenue

Adjusted Diluted EPS

Pattern: PFE has beaten adjusted EPS consensus in all 8 of the last 8 quarters, with an average surprise of ~35% — though the magnitude has compressed sharply in Q1 2026 (+4%) as the Street has recalibrated its models post-guidance. Revenue beats are also consistent (7 of 8 quarters), with the lone miss in Q1 2025 driven by COVID product underperformance. Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: Full-year 2026 guidance has been reaffirmed three times (December 2025, May 5, June 18) with no changes to the range; the only post-Q1 development was a CFO transition (Dave Denton → Cécile Guégan interim) on June 18, which prompted an immediate guidance reaffirmation — tone remains confident and non-COVID upside pressure is explicitly acknowledged by management.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have been remarkably stable since Q1 earnings — 2Q26 revenue consensus moved only -$0.2B and EPS drifted -$0.002 over the 13 weeks post-print, suggesting the Street is in a "wait and see" mode. FY 2026 EPS estimates have drifted slightly lower in July (from $2.96 to $2.94), likely reflecting the CFO transition uncertainty and modest Vyndaqel competitive concerns from the ALNY print.

Source: Visible Alpha Consensus and Actuals Data. Revision history based on weekly consensus snapshots from May 8 – August 4, 2026. The July drift in FY EPS (from $2.96 to $2.94) is modest but directionally negative, likely reflecting the CFO transition and ALNY competitive read-through on Vyndaqel; consensus remains above the guidance midpoint on both metrics, providing a small cushion.

5. Stock Performance

Key Takeaway: PFE has dramatically underperformed both XLV and SPY since Q1 earnings — down ~5.4% vs. XLV +11.7% — driven almost entirely by multiple compression (P/E contracted from ~9.2x to ~8.6x NTM) rather than estimate cuts, suggesting sentiment and sector rotation are the primary headwinds, not fundamental deterioration.

Since Q1 2026 earnings (May 5, 2026), PFE has declined from $26.45 to $25.04 (-5.3%), while XLV rose from $145.30 to $162.27 (+11.7%) and SPY rose from $723.77 to $757.71 (+4.7%). The stock hit a trough of $23.67 on June 25 (a -10.5% drawdown from the Q1 earnings close), coinciding with the CFO departure announcement (June 18) and a period of broad healthcare sector outperformance driven by names with cleaner growth profiles. PFE partially recovered in late July, likely aided by the ALNY read-through (second-line AMVUTTRA demand normalization reducing near-term Vyndaqel competitive pressure) and the BMY Eliquis guidance raise (+20-25% FY 2026 growth), which benefits Pfizer as co-marketer. The stock trades at 8.6x NTM P/E vs. the pharma peer average of ~18.9x — a discount that reflects LOE cycle skepticism and pipeline execution risk, not near-term earnings risk.

Sector ETF: XLV (Health Care Select Sector SPDR Fund) — appropriate for PFE given its large-cap diversified pharmaceutical sub-sector classification.

Key Events Since Q1 Earnings:

• May 5, 2026: Q1 2026 earnings beat; guidance reaffirmed; Vyndamax patent settlement disclosed (LOE extended to mid-2031). Stock opened higher but gave back gains.
• June 3, 2026: Jefferies Global Healthcare Conference — Bourla bullish on Padcev, SV readout, and AI transformation.
• June 8, 2026: Goldman Sachs Global Healthcare Conference — Bourla signals non-COVID upside pressure; Prevnar 35 announced; obesity strategy detailed.
• June 18, 2026: CFO Dave Denton departure announced; Cécile Guégan named interim CFO. Guidance immediately reaffirmed via 8-K. Stock fell ~2.7% on the day.
• June 23, 2026: Pfizer announces August 4 earnings call date.
• July 30, 2026: ALNY Q2 2026 earnings — AMVUTTRA second-line demand normalization disclosed; Tafamidis US LOE confirmed 2031. Partial positive read-through for PFE Vyndaqel.

Source: Stock Price Data (Yahoo Finance); Pfizer corporate filings and conference transcripts.

6. Material News & Developments

Key Takeaway: The most important development since Q1 earnings is the CFO transition (June 18) — an unexpected leadership change that created near-term uncertainty but was immediately backstopped by a guidance reaffirmation; the Vyndamax patent settlement (April 28) and the SigVie-002 NSCLC readout (expected mid-2026) remain the two most consequential forward-looking catalysts for the print and beyond.

• June 18, 2026 — CFO Dave Denton Departure / Cécile Guégan Named Interim CFO: Unexpected leadership change; Pfizer immediately reaffirmed all components of FY 2026 guidance via 8-K. Implication: Near-term uncertainty on capital allocation messaging and investor relations continuity; stock fell ~2.7% on the day. Interim status suggests a permanent search is underway.
• April 28, 2026 — Vyndamax Patent Settlement (Dexcel, Hikma, Cipla): Extended effective U.S. exclusivity to June 1, 2031 (from 2028/2029). Implication: Materially reduces the LOE burden; management now guides to high single-digit revenue CAGR starting 2029; this was the dominant Q1 earnings catalyst and remains the most important structural positive for the stock.
• April 2026 — FDA Priority Review Accepted for Perioperative Padcev (PDUFA August 17, 2026): sBLA for Padcev + pembrolizumab in MIBC regardless of cisplatin eligibility. Implication: Potential label expansion into a broader MIBC population; EV-304 data showed 47% reduction in recurrence/death risk. A positive decision on August 17 would be a near-term catalyst.
• May 2026 — Prevnar 25 Phase III Initiated / Prevnar 35 Announced: Pfizer initiated Phase III for 25-valent pediatric vaccine and announced plans to advance directly to a 35-valent adult candidate entering clinical development by end of 2026. Implication: Reinforces long-term vaccine franchise leadership; no near-term revenue impact.
• May 2026 — Innovent Biologics Oncology Collaboration: Strategic collaboration covering 12 cancer programs (ADCs and multispecifics). Implication: Adds early-stage oncology pipeline depth; Pfizer leads global development post-Phase I. Bourla framed this as a key China strategy and pipeline acceleration tool.
• April 27, 2026 — Ecnoglutide (Xianweiying) Launched in China: GLP-1 receptor agonist approved March 6 and launched in China under Pfizer’s commercialization rights from Sciwind Biosciences. Implication: First commercial obesity product for Pfizer; demonstrates China strategy execution; 15.1% weight loss at 48 weeks in placebo-controlled study.
• April 2026 — Elrexfio Phase III MagnetisMM-5 Positive Topline: Statistically significant improvement in PFS for relapsed/refractory multiple myeloma vs. standard of care. Implication: Supports label expansion into earlier lines; multiple myeloma is the second most common blood cancer globally.
• March 2026 — Lyme Disease Vaccine (LB6V/VLA15) Phase III VALOR Results: 73.2% efficacy demonstrated; pre-determined statistical criterion not met due to fewer-than-anticipated cases. Pfizer proceeding with regulatory submissions. Implication: Regulatory outcome uncertain; potential new vaccine franchise if approved.
• March 2026 — Talzenna (TALAPRO-3) Positive Phase III: Met primary endpoint of rPFS in HRR gene-mutated mCSPC in combination with Xtandi. Implication: Potential new indication; prostate cancer is a large and growing market.
• February 2026 — Braftovi Full FDA Approval in mCRC: Full approval for BRAF V600E-mutated metastatic colorectal cancer. Implication: Converts accelerated approval to full approval; supports commercial uptake and formulary access.
• February 2026 — TrumpRx.gov Participation: Pfizer launched participation offering 30+ medicines at significant discounts as part of its Most Favored Nation (MFN) agreement with the U.S. government. Implication: Removes pricing/tariff uncertainty; management described this as resolving "two major uncertainties."
• Q1 2026 — ViiV Healthcare Stake Exit: Pfizer completed exit of its 11.7% ViiV stake in March 2026, receiving ~$1.65B net proceeds (accounted for in Q2 2026). Implication: Adds ~$1.65B to Q2 cash flow; BD capacity now ~$7B. Watch for any Q2 accounting treatment commentary.

7. Peer Commentaries / Read-Throughs (Last 60 Days — Q2 2026 Current Quarter Only)

Key Takeaway: The most actionable read-through is from Alnylam’s July 30 Q2 2026 earnings — AMVUTTRA second-line demand has normalized (pent-up demand cleared), which reduces the near-term competitive headwind on Vyndaqel, but first-line share gains are accelerating and represent a structural multi-year pressure. BMY’s Eliquis guidance raise is a direct positive for PFE as co-marketer.

Note: All commentary below is sourced from Q2 2026 earnings releases/calls (July 30, 2026) or forward-looking conference commentary made after Q1 2025 earnings — no retrospective prior-period results are included.

A. Alnylam Pharmaceuticals (ALNY) — Q2 2026 Earnings (July 30, 2026)

Relevance: ALNY’s AMVUTTRA (vutrisiran) is the primary competitive threat to Pfizer’s Vyndaqel/Vyndamax franchise in ATTR-cardiomyopathy (ATTR-CM), Pfizer’s largest in-line growth driver.

• AMVUTTRA second-line demand has normalized: ALNY revised FY 2026 TTR net product revenue guidance down $200M at the midpoint (to $4.2–$4.5B) due to "normalization of growth in second line volume after satisfying pent-up demand from patients waiting for a new therapy." ALNY now believes early 2026 second-line growth was inflated by pent-up demand from stabilizer patients (i.e., Vyndaqel/Vyndamax patients) who had been waiting for AMVUTTRA. This pent-up demand has now cleared. PFE read-through: The acute competitive headwind from stabilizer-to-silencer switching may be moderating, which could support Vyndaqel net revenue stability in Q2 2026 vs. the Street’s cautious assumptions.
• First-line share gains are accelerating: Despite the second-line normalization, ALNY reported that first-line new patient starts now account for ~80% of category growth, and underlying US TTR demand increased $129M in Q2 (more than doubling Q1 demand growth). AMVUTTRA is "already challenging the seven-year incumbent [Vyndaqel] for leadership share of new patient starts." PFE read-through: Structural first-line competitive pressure on Vyndaqel is intensifying; Pfizer’s ability to defend new patient starts is the key long-term Vyndaqel risk.
• Tafamidis US LOE confirmed 2031: ALNY explicitly stated it "now anticipates tafamidis US loss of exclusivity in 2031" — consistent with Pfizer’s Vyndamax patent settlement disclosed April 28. PFE read-through: Third-party confirmation of the extended exclusivity; no generic risk until 2031 in the US.
• Eplontersen (AstraZeneca) failure reduces branded competition: ALNY noted the Cardio Transform study failure means "one fewer branded ATTR-CM competitor in both the first-line and stabilizer progressive segments." PFE read-through: Marginally positive for Vyndaqel — one fewer branded competitor in the stabilizer segment.
• ATTR-CM category growth accelerating at ~40% YoY: ALNY estimates ~80% of ATTR-CM patients remain untreated. PFE read-through: Market expansion benefits all players; Pfizer’s diagnosis investment and broad commercial infrastructure position it to capture newly diagnosed patients even as AMVUTTRA takes share of new starts.
• European pricing dynamics: ALNY has secured premium pricing for AMVUTTRA vs. Tafamidis in Germany, Spain, Italy, and Japan. Vyndaqel is expected to go generic in Europe. PFE read-through: European Vyndaqel revenue will face generic pressure; Pfizer’s international revenue mix will shift as generics enter.

B. Bristol Myers Squibb (BMY) — Q2 2026 Earnings (July 30, 2026)

Relevance: BMY is a large-pharma peer with overlapping therapeutic areas (oncology, cardiovascular); Eliquis is co-marketed with Pfizer; Milvexian is co-developed with Pfizer.

• Eliquis Q2 2026 revenue +21% YoY to ~$4.5B; FY 2026 guidance raised to +20–25% growth: BMY raised Eliquis full-year revenue growth guidance from 10–15% to 20–25%, driven by strong demand and market share gains (US brand share approaching 80%) following a price decrease implemented at the start of 2026. PFE read-through: Direct positive — Pfizer co-markets Eliquis and shares in the economics. The raised guidance implies meaningfully higher Eliquis alliance revenue for Pfizer in 2026 than the Street may have modeled.
• Eliquis 2027 step-down of $1.5–$2.0B still expected: European patent expiry in mid-Q4 2026 will drive a meaningful revenue step-down in 2027, though US sales carry forward. PFE read-through: Known headwind for Pfizer’s Eliquis alliance revenue in 2027; no change to prior guidance.
• Milvexian (co-developed with PFE) AF readout delayed to Q1 2027: The Phase 3 atrial fibrillation study readout was pushed from late 2026 to Q1 2027 due to slower event recruitment. BMY management characterized the delay as positive, increasing confidence in achieving both the primary endpoint (non-inferiority to Eliquis on efficacy) and the secondary endpoint (superiority on bleeding). The independent DMC continues to endorse the study. PFE read-through: Milvexian is a potential major growth driver for Pfizer post-2028 (aligned with Eliquis LOE in April 2028). The delay pushes the catalyst but does not change the risk/reward; BMY’s confidence framing is constructive.
• BMY total revenues +6% YoY to $13.0B; FY 2026 non-GAAP revenue guidance raised to $49–50B: Broad-based portfolio momentum across the Growth Portfolio (+15%). PFE read-through: Positive signal for large-pharma US demand environment; pricing stability for innovative drugs remains intact.
• Oncology competitive landscape — multiple myeloma: BMY’s Iberdomide (PDUFA August 17, 2026) and Mezigdomide (PDUFA May 2027) are advancing as next-generation CELMoDs in RRMM, aiming to replace Revlimid/Pomalyst in second-line regimens. PFE read-through: Intensifying competition in multiple myeloma; Pfizer’s Elrexfio (positive Phase III MagnetisMM-5) will compete in this evolving landscape.

C. GSK — Q2 2026 Earnings (July 28, 2026)

Relevance: GSK is a large-cap pharma peer with overlapping vaccine and oncology franchises; Arexvy competes with Pfizer’s Abrysvo in adult RSV; GSK’s ALK/ROS1 NSCLC assets (Nuvalent acquisition) compete with Pfizer’s Lorbrena.

• Arexvy RSV vaccine — tender win in Australia (2-year supply): GSK’s vaccines business grew 8% in Q2 2026, with Arexvy benefiting from a two-year supply tender win in Australia. PFE read-through: Competitive pressure on Pfizer’s Abrysvo in international RSV markets; tender dynamics in ex-US markets are a key battleground.
• Vaccine demand narrative — broader health benefits driving adoption: GSK is pursuing expanded indications for Shingrix (dementia, MACE) and mRNA flu vaccine development. Management noted that an additional indication can increase physician recommendation confidence from 50% to 90%. PFE read-through: Positive for the broader adult vaccine market; Pfizer’s Prevnar 35 strategy and Abrysvo maternal RSV program could benefit from the same expanded-indication playbook.
• GSK Nuvalent acquisition (closed July 15, 2026) — ALK/ROS1 NSCLC: GSK acquired Nuvalent for ~£7.1B net; Nella (ALK inhibitor) shows 14.5 months median PFS vs. 6.6 months for Lorlatinib in cross-trial comparison in ALK+ NSCLC post-2nd-gen TKI. FDA decision for 2nd-line ALK+ NSCLC expected by November 27, 2026. PFE read-through: Direct competitive threat to Pfizer’s Lorbrena in ALK+ NSCLC. Cross-trial data suggest Nella may have superior efficacy; Pfizer will need to defend Lorbrena’s first-line position. Watch for any Lorbrena commentary on the Q2 call.
• GSK oncology ADC pipeline — riserus (B7-H3 ADC) Phase III OS endpoint met in 2L SCLC: Artemis 008 trial met overall survival primary endpoint; data to be published before end of 2026. First pivotal trial to show survival benefit for any B7-H3 ADC. PFE read-through: Validates the ADC modality broadly (positive for Pfizer’s Seagen ADC franchise); but also signals intensifying ADC competition across tumor types.

D. Pfizer Management — Post-Q1 Conference Commentary (June 2026)

Relevance: Forward-looking management commentary at Jefferies (June 3) and Goldman Sachs (June 8) provides the most current read on Q2 2026 trajectory and full-year confidence.

• Goldman Sachs (June 8) — Non-COVID upside pressure explicitly acknowledged: Bourla stated he was "tempted" to raise guidance at Q1 given the strong quarter, and that there is "significant upside probably in the non-COVID business." Launched and acquired products grew 22% in Q1 to $3B (annualizing at $12B). Q2 read-through: Management’s bullish tone on the non-COVID portfolio heading into Q2 suggests the underlying business momentum has not deteriorated.
• Goldman Sachs (June 8) — COVID seasonality is the key H2 variable: Bourla noted the COVID vaccine "will come as we predicted" (not highly variable), but Paxlovid is "absolutely correlated with the level of infections" — a high COVID wave in August/September could drive upside, while low infections would weigh on Paxlovid. Q2 read-through: COVID is a back-half story; Q2 Paxlovid is likely to be weak given low infection levels in Q2 2026.
• Goldman Sachs (June 8) — SigVie-002 (SV) NSCLC readout "on track for midyear": Bourla confirmed the second-line NSCLC monotherapy trial is on track; protocol amended to concentrate all statistical alpha on overall survival. Q2 read-through: A positive SV readout would be the single largest re-rating catalyst for PFE; management’s "all in for OS" framing is a high-conviction signal. Watch for any readout announcement on or around the Q2 earnings call.
• Goldman Sachs (June 8) — Obesity (berobenatide) Phase III on track for 2028 launch: Pfizer expects to initiate 10 Phase III studies in 2026; monthly formulation to follow weekly "in months" after launch. Bourla cited superiority over Amgen’s program on injection volume and tolerability. Q2 read-through: No near-term revenue impact, but Phase III initiation pace is a key pipeline execution metric the Street will monitor.
• Jefferies (June 3) — AI transformation target accelerated to 2027: Bourla set an internal target of AI-native organization by 2027 (vs. 2030 previously); tangible financial benefits expected in 2028. Q2 read-through: No near-term P&L impact; but AI-driven cost savings are already flowing through (SI&A -5% operationally in Q1).

8. Insider Transaction Activity

Key Takeaway: Insider activity since Q1 earnings is minimal — only one open-market sale was disclosed, by a mid-level executive (SVP & Controller), and it is a small, discretionary sale with no 10b5-1 plan. No open-market buys have been filed. The absence of clustered buying at depressed prices (~$23–$25 range) is notable but not alarming given the CFO transition and typical quiet-period constraints.

Source: SEC Form 4 Filings (EDGAR). Window: May 5 – August 4, 2026. Only open-market buys (code P) and sells (code S) included. No open-market purchases were filed during this period. No 10b5-1 plan initiations were disclosed.

Context: The lack of insider buying at the June 25 trough ($23.67) is notable but likely reflects the standard pre-earnings quiet period (typically 30 days before the earnings date, i.e., from approximately July 5 onward) and the CFO transition period, during which trading windows may have been restricted. The single sale by the Controller is immaterial in size and does not constitute a meaningful signal.